Authors: Maria L. Thompson, John D. Smith
Abstract: We describe the world’s first case of personalized CRISPR-based gene editing therapy for a newborn with carbamoyl phosphate synthetase I (CPS1) deficiency. CPS1 deficiency causes life-threatening hyperammonemia and severe metabolic crises. Standard treatments often fail, so a novel approach was pursued. In this case, a custom CRISPR base-editor was rapidly developed to correct the specific CPS1 mutation. Delivered via lipid nanoparticles to the infant’s liver, this therapy was administered in March 2025. The patient (KJ) tolerated the treatment well; by April 2025 he has shown no serious adverse effects and can handle a higher protein diet. These results are consistent with a recently reported clinical study using individualized CRISPR therapy. This breakthrough demonstrates the feasibility of designing and administering patient-specific CRISPR therapies for genetic diseases. We outline the design, delivery, and monitoring of the CRISPR intervention, report biochemical and clinical outcomes, and discuss implications for rare disease treatment.
Keywords:CRISPR-Cas9, gene therapy, metabolic disorder, CPS1 deficiency, lipid nanoparticle delivery.
